Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

BACKGROUND: Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors. Bevacizumab is an anti-VEGF-A monoclonal antibody with clinical benefit in previously treated metastatic colorectal cancer (mCRC). METHODS: Patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Cunningham, D, Wong, R P W, D'Haens, G, Douillard, J-Y, Robertson, J, Stone, A M, Van Cutsem, E
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2013
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3593537/
https://ncbi.nlm.nih.gov/pubmed/23299530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.545
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items